Chronic lymphocytic leukemia, autoimmune hemolytic anemia and ibrutinib: a case report and review of the literature
- 5 October 2015
- journal article
- review article
- Published by Taylor & Francis Ltd in Leukemia & Lymphoma
- Vol. 57 (3), 735-737
- https://doi.org/10.3109/10428194.2015.1071489
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Ibutinib-Associated Autoimmune Hemolytic Anemia in CLLBlood, 2014
- Autoimmune Hemolytic Anemia and Immune Mediated Thrombocytopenia in the Phase III RESONATETM Study of Ibrutinib Vs Ofatumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Including a Case ReportBlood, 2014
- Incidence of Autoimmune Cytopenias (AIC) in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (CLL/SLL) Patients (pts) Treated with IbrutinibBlood, 2014
- Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid LeukemiaThe New England Journal of Medicine, 2014
- Autoimmune cytopenias in chronic lymphocytic leukemiaAmerican Journal of Hematology, 2014
- Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytesBlood, 2013
- Chronic lymphocytic leukemia and autoimmunity: a systematic reviewHaematologica, 2011
- The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancyProceedings of the National Academy of Sciences of the United States of America, 2010
- Disease-Specific Complications of Chronic Lymphocytic LeukemiaHematology, 2008